Artesunate plus Amodiaquine — Competitive Intelligence Brief

Artesunate plus Amodiaquine (Artesunate plus Amodiaquine) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: Antimalarial combination therapy. Area: Infectious Disease.

marketed Antimalarial combination therapy Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis) Infectious Disease Small molecule

Target snapshot

Artesunate plus Amodiaquine (Artesunate plus Amodiaquine) — Bernhard Nocht Institute for Tropical Medicine. Artesunate and amodiaquine work synergistically to kill malaria parasites by generating reactive oxygen species and disrupting parasite metabolism.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Artesunate plus Amodiaquine TARGET	Artesunate plus Amodiaquine	Bernhard Nocht Institute for Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum (multiple parasite targets including heme detoxification pathway and DNA synthesis)
Amodiaquine-artesunate (ASAQ)	Amodiaquine-artesunate (ASAQ)	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Plasmodium falciparum heme polymerase; artemisinin-derived endoperoxide bridge
IPTp-DP	IPTp-DP	Kenya Medical Research Institute	marketed	Antimalarial combination therapy	Plasmodium falciparum (malaria parasite)
lumefantrine plus artemether	lumefantrine plus artemether	Centers for Disease Control and Prevention	marketed	Antimalarial combination therapy	Malaria parasite heme metabolism and hemozoin formation
SP-IPTp	SP-IPTp	London School of Hygiene and Tropical Medicine	marketed	Antimalarial combination therapy	Plasmodium falciparum dihydrofolate reductase (sulfadoxine-pyrimethamine); hemozoin formation (piperaquine)
Coadministered Artesunate plus Amodiaquine	Coadministered Artesunate plus Amodiaquine	Professor Anders Björkman	marketed	Antimalarial combination therapy	Plasmodium falciparum heme metabolism and protein synthesis
WHO-recommended periodic presumptive treatment	WHO-recommended periodic presumptive treatment	University of Washington	marketed	Antimalarial combination therapy

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (Antimalarial combination therapy class)

1. London School of Hygiene and Tropical Medicine · 4 drugs in this class
2. Kenya Medical Research Institute · 2 drugs in this class
3. University of Oxford · 2 drugs in this class
4. Centers for Disease Control and Prevention · 2 drugs in this class
5. University of Melbourne · 1 drug in this class
6. Bernhard Nocht Institute for Tropical Medicine · 1 drug in this class
7. University of Washington · 1 drug in this class
8. Fundação de Medicina Tropical Dr. Heitor Vieira Dourado · 1 drug in this class
9. Medicines for Malaria Venture · 1 drug in this class
10. Professor Anders Björkman · 1 drug in this class